Plasma levels of pS129 but not total α-synuclein were higher in PD subjects compared to healthy controls on the first presentation, but during the follow-up period of the PD patients, the levels of total α-synuclein in the plasma increased and that of pS129 remained unaltered (Foulds et al., 2013). This evidence concerns the gene SNCA and Parkinson disease.